Navigation Links
Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
Date:4/10/2013

JUPITER, Fla., April 10, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that its President and CEO, Mark Emalfarb , will speak at the Advanced Biofuels Leadership Conference in Washington, DC, during its conference session: Hot Technologies & Products, at 2:30 p.m. EDT on April 17, 2013.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

The Advanced Biofuels Leadership Conference has become one of the largest gatherings of CEOs, senior executives, strategic partners, financiers, equity analysts, policymakers and industry suppliers in the Advanced Biofuels & Renewable Chemicals and Biomaterials industries in North America. The conference brings these leaders together to showcase leading companies, technologies and business strategies, and to discuss crucial technologies, partnership, financial strategies, and energy, agricultural, tax and trade policy issues, that together are charting the future of the Biofuels & Renewable Chemicals and Biomaterials industries in the US and Internationally.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International To Present At World Biofuels Markets
2. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
3. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
4. 12th U.S. Patent Issued To Dyadic International
5. Dyadic International Reports 2012 Third Quarter Financial Results
6. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
7. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
8. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
9. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
10. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
11. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):